Table 3.
Factors associated with ART uptake and VL suppression among HIV-infected patients in care in the ARCs (2011), Belgium
| ART uptake | VL suppression | ||||||
|---|---|---|---|---|---|---|---|
| Characteristic | On ART | OR for no ART uptake (95 % CI) | AORa for no ART uptake (95 % CI) | AORb for no ART uptake (95 % CI) | Undetectable VL | OR for detectable VL (95 % CI) | AORa for detectable VL (95 % CI) |
| Sex | |||||||
| Male | 84.5 % | 1 | 1 | 1 | 83.7 % | 1 | 1 |
| Female | 84.9 % | 0.97 (0.87–1.09) | 1.38 (1.14–1.67) | 1.16 (0.85–1.58) | 82.9 % | 1.06 (0.93–1.19) | 0.84 (0.70–1.01) |
| Age at diagnosis | |||||||
| <40 years | 84.0 % | 1 | 1 | 1 | 82.3 % | 1 | 1 |
| ≥40 years | 85.5 % | 0.89 (0.78–1.01) | 0.88 (0.76–1.02) | 0.74 (0.60–0.91) | 85.2 % | 0.81 (0.70–0.93) | 0.83 (0.71–0.97) |
| Way of transmission | |||||||
| Heterosexual | 85.9 % | 1 | 1 | 1 | 82.6 % | 1 | 1 |
| MSM | 81.8 % | 1.36 (1.19–1.55) | 1.54 (1.27–1.88) | 0.98 (0.73–1.32) | 84.8 % | 0.85 (0.74–0.98) | 0.88 (0.72–1.07) |
| IDU | 85.6 % | 1.02 (0.66–1.59) | 1.01 (0.64–1.60) | 0.75 (0.27–2.11) | 82.5 % | 1.01 (0.65–1.56) | 1.04 (0.66–1.65) |
| Nationality | |||||||
| Belgian | 83.8 % | 1 | 1 | 1 | 85.1 % | 1 | 1 |
| SSA | 86.4 % | 0.81 (0.71–0.93) | 0.87 (0.73–1.05) | 0.89 (0.65–1.21) | 81.3 % | 1.31 (1.14–1.52) | 1.25 (1.04–1.51) |
| European | 82.5 % | 1.10 (0.88–1.37) | 1.14 (0.91–1.44) | 0.84 (0.61–1.15) | 84.2 % | 1.07 (0.83–1.38) | 1.01 (0.77–1.32) |
| Other | 81.9 % | 1.14 (0.90–1.45) | 1.13 (0.89–1.45) | 1.17 (0.81–1.67) | 81.1 % | 1.33 (1.03–1.73) | 1.21 (0.92–1.59) |
| Reason for testing | |||||||
| Patient’s request | 76.7 % | 1 | 1 | 1 | 82.6 % | 1 | 1 |
| Clinical arguments | 86.2 % | 0.53 (0.45–0.62) | 0.57 (0.48–0.67) | 0.77 (0.61–0.97) | 82.9 % | 0.98 (0.82–1.18) | 0.96 (0.79–1.16) |
| Preoperative | 78.8 % | 0.89 (0.62–1.27) | 0.95 (0.64–1.40) | 1.82 (0.95–3.52) | 88.2 % | 0.64 (0.38–1.07) | 0.65 (0.38–1.11) |
| Other | 83.5 % | 0.65 (0.54–0.78) | 0.73 (0.60–0.89) | 0.92 (0.68–1.25) | 83.7 % | 0.93 (0.75–1.15) | 0.87 (0.69–1.10) |
| CD4 at first visit | |||||||
| CD4≥350 | 58.5 % | 1 | 1 | / | 76.5 % | 1 | 1 |
| CD4≥200 & <350 | 88.0 % | 0.19 (0.15–0.25) | 0.19 (0.14–0.26) | / | 78.2 % | 0.91 (0.70–1.17) | 0.83 (0.62–1.10) |
| CD4<200 | 94.0 % | 0.09 (0.06–0.13) | 0.09 (0.06–0.14) | / | 74.6 % | 1.10 (0.87–1.41) | 1.03 (0.78–1.37) |
| Time since HIV diagnosis | |||||||
| <1 year | 54.2 % | 1 | 1 | 1 | 49.2 % | 1 | 1 |
| 1 – <5 years | 78.3 % | 0.33 (0.28–0.39) | 0.32 (0.27–0.39) | 0.26 (0.21–0.33) | 81.5 % | 0.22 (0.18–0.27) | 0.22 (0.17–0.27) |
| 5 – <10 years | 89.3 % | 0.14 (0.12–0.17) | 0.13 (0.11–0.16) | 0.12 (0.07–0.19) | 88.4 % | 0.13 (0.10–0.16) | 0.12 (0.09–0.15) |
| ≥10 years | 94.5 % | 0.07 (0.06–0.08) | 0.06 (0.05–0.07) | / | 85.9 % | 0.16 (0.13–0.20) | 0.14 (0.11–0.18) |
p < 0.05, statistically significant variables presented in boldface
aAdjusted for sex, age at diagnosis, nationality, way of transmission
bAdditional adjustment for CD4 value at first visit (only includes patients diagnosed between 2006 and 2011, n = 2437)